Should We Increase GFR with Bardoxolone in Alport Syndrome?

被引：33

作者：

Baigent, Colin ^{[1
]}

Lennon, Rachel ^{[2
,3
]}

机构：

[1] Univ Oxford, Nuffield Dept Populat Hlth, Populat Hlth Res Unit, MRC, Oxford, England

[2] Univ Manchester, Sch Biol Sci, Dept Paediat Nephrol, Wellcome Trust Ctr Cell Matrix Res, Manchester, Lancs, England

[3] Royal Manchester Childrens Hosp, Manchester, Lancs, England

来源：

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2018年 / 29卷 / 02期

关键词：

CHRONIC KIDNEY-DISEASE; METHYL;

D O I：

10.1681/ASN.2017101062

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：357 / 359

页数：3

共 9 条

[1] Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease-Improving Global Outcomes (KDIGO) Controversies Conference [J].

Baigent, Colin ;

Herrington, William G. ;

Coresh, Josef ;

Landray, Martin J. ;

Levin, Adeera ;

Perkovic, Vlado ;

Pfeffer, Marc A. ;

Rossing, Peter ;

Walsh, Michael ;

Wanner, Christoph ;

Wheeler, David C. ;

Winkelmayer, Wolfgang C. ;

McMurray, John J. V. .

KIDNEY INTERNATIONAL, 2017, 92 (02) :297-305

[2] The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin [J].

Besarab, A ;

Bolton, WK ;

Browne, JK ;

Egrie, JC ;

Nissenson, AR ;

Okamoto, DM ;

Schwab, SJ ;

Goodkin, DA .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (09) :584-590

[3] Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease [J].

de Zeeuw, Dick ;

Akizawa, Tadao ;

Audhya, Paul ;

Bakris, George L. ;

Chin, Melanie ;

Christ-Schmidt, Heidi ;

Goldsberry, Angie ;

Houser, Mark ;

Krauth, Melissa ;

Heerspink, Hiddo J. Lambers ;

McMurray, John J. ;

Meyer, Colin J. ;

Parving, Hans-Henrik ;

Remuzzi, Giuseppe ;

Toto, Robert D. ;

Vaziri, Nosratola D. ;

Wanner, Christoph ;

Wittes, Janet ;

Wrolstad, Danielle ;

Chertow, Glenn M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (26) :2492-2503

[4] Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts [J].

Gansevoort, Ron T. ;

Matsushita, Kunihiro ;

van der Velde, Marije ;

Astor, Brad C. ;

Woodward, Mark ;

Levey, Andrew S. ;

de Jong, Paul E. ;

Coresh, Josef .

KIDNEY INTERNATIONAL, 2011, 80 (01) :93-104

[5] Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-Analysis [J].

Heerspink, Hiddo J. Lambers ;

Kropelin, Tobias F. ;

Hoekman, Jarno ;

de Zeeuw, Dick .

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2015, 26 (08) :2055-2064

[6] A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas [J].

Hong, David S. ;

Kurzrock, Razelle ;

Supko, Jeffrey G. ;

He, Xiaoying ;

Naing, Aung ;

Wheler, Jennifer ;

Lawrence, Donald ;

Eder, Joseph Paul ;

Meyer, Colin J. ;

Ferguson, Deborah A. ;

Mier, James ;

Konopleva, Marina ;

Konoplev, Sergej ;

Andreeff, Michael ;

Kufe, Donald ;

Lazarus, Hillard ;

Shapiro, Geoffrey I. ;

Dezube, Bruce J. .

CLINICAL CANCER RESEARCH, 2012, 18 (12) :3396-3406

[7]

Meyer C, 2017, NEPHROL DIAL TRAN S3, V32

[8] Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes [J].

Pergola, Pablo E. ;

Raskin, Philip ;

Toto, Robert D. ;

Meyer, Colin J. ;

Huff, J. Warren ;

Grossman, Eric B. ;

Krauth, Melissa ;

Ruiz, Stacey ;

Audhya, Paul ;

Christ-Schmidt, Heidi ;

Wittes, Janet ;

Warnock, David G. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (04) :327-336

[9] Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease [J].

Ruiz, Stacey ;

Pergola, Pablo E. ;

Zager, Richard A. ;

Vaziri, Nosratola D. .

KIDNEY INTERNATIONAL, 2013, 83 (06) :1029-1041

← 1 →